BDX Becton Dickinson
Q4 2025 10-Q
Filed: Feb 9, 2026Period ending Dec 31, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR Becton Dickinson (BDX) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 9, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ4 2025 10-Q
Management Discussion & Analysis
- • Revenue $5.252B, up 1.6% YoY from $5.168B, driven by 1.2% FX impact; U.S. revenue growth 2.6%, international revenue flat (+0.2%)
- • Gross profit margin 45.9% vs 43.3% YoY; operating performance margin declined 1.3%; selling/admin expense 26.5% vs 25.5%; R&D expense 5.8% vs 6.6%
Risk Factors
- • No material changes to risk factors from 2025 Annual Report
- • Product liability and regulatory compliance risks from healthcare regulations remain significant
Quarterly Financial SummaryXBRL
Revenue
$5.3B
▲ +1.6% YoY
Net Income
$382M
▲ +26.1% YoY
Operating Margin
10.5%
▲ +174bp YoY
Net Margin
7.3%
▲ +141bp YoY
ROE
1.5%
▲ +31bp YoY
Total Assets
$54.8B
▲ +0.3% YoY
EPS (Diluted)
$1.34
▲ +28.8% YoY
Operating Cash Flow
$657M
▼ -5.2% YoY
Source: XBRL data from Becton Dickinson Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Becton Dickinson Quarterly Reports
Get deeper insights on Becton Dickinson
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.